Metastatic non–clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.

Nils Kroeger(Universitätsmedizin Greifswald), Daniel Yick Chin Heng(University of Calgary), Min‐Han Tan(National Cancer Centre Singapore), Sumanta K. Pal(City of Hope), Ulka N. Vaishamayan(Wayne State University), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Scott North, Sun Young Rha(Yonsei University), Wanling Xie(Dana-Farber Cancer Institute), Jennifer J. Knox(National Cancer Center), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Sandy Srinivas(Stanford University), Mary J. MacKenzie(Cancer Care Ontario), Neeraj Agarwal(University of Utah), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Journal of Clinical Oncology
February 20, 2013
10.1200/jco.2013.31.6_suppl.396
Cited by 0

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.3k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k